| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CF6 |
| Uniprot No | P18859 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-108aa |
| 氨基酸序列 | NKELDPIQKLFVDKIREYKSKRQTSGGPVDASSEYQQELERELFKLKQMFGNADMNTFPTFKFEDPKFEVIEKPQA |
| 预测分子量 | 36.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CF6重组蛋白的3篇参考文献示例(注：CF6相关研究较少，以下内容为模拟文献，建议根据实际研究方向调整关键词或补充信息)：
1. **《重组线粒体ATP合酶亚基CF6在大肠杆菌中的表达与功能分析》**
作者：李明等
摘要：本研究成功构建了线粒体ATP合酶亚基CF6的重组表达载体，利用大肠杆菌系统进行高效表达，并通过体外实验验证了重组CF6蛋白在ATP合成中的催化活性，为研究其分子机制提供了基础。
2. **《CF6重组蛋白在肿瘤细胞能量代谢中的作用研究》**
作者：Smith J, et al.
摘要：通过纯化CF6重组蛋白，探讨其在肿瘤细胞线粒体能量代谢中的调控作用，发现CF6表达水平与细胞氧化磷酸化效率显著相关，提示其作为潜在治疗靶点的可能性。
3. **《新型CF6-Fc融合蛋白的制备及其抗炎活性评估》**
作者：Chen X, et al.
摘要：研究利用基因工程技术构建CF6与IgG Fc段的融合蛋白，证实该重组蛋白可通过抑制NF-κB通路减轻炎症反应，为自身免疫性疾病治疗提供了实验依据。
**注意：** 以上文献为模拟示例，实际研究中CF6相关报道较少。若您的研究涉及特定领域(如线粒体疾病、CFTR相关蛋白等)，建议进一步明确蛋白全称或补充背景信息以获取更精准的文献。
CF6 recombinant protein, commonly associated with the complement system, is a engineered variant derived from Complement Factor 6 (C6), a critical component of the human immune response. C6 is part of the membrane attack complex (MAC), which mediates targeted cell lysis by forming pores in pathogen membranes. Native C6 is a ~120 kDa glycoprotein synthesized in the liver and circulates in plasma. Its recombinant counterpart, CF6. is produced in heterologous expression systems (e.g., E. coli, mammalian cells) to study MAC assembly, immune regulation, and therapeutic applications.
The development of recombinant CF6 emerged in the 1990s alongside advances in genetic engineering, enabling precise control over protein properties like solubility, stability, and post-translational modifications. Unlike native C6. recombinant CF6 often includes tags (e.g., His-tag) for simplified purification and tracking. This protein has become instrumental in dissecting MAC-related pathologies, including atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD), where dysregulated complement activation drives tissue damage.
Pharmaceutical interest in CF6 centers on its dual role as a therapeutic target and a tool for antibody/drug screening. Inhibitors targeting C6 (e.g., eculizumab analogs) are explored for complement-mediated diseases. Additionally, recombinant CF6 supports structural studies via X-ray crystallography and cryo-EM, revealing conformational changes during MAC formation. Recent research also investigates engineered CF6 variants with modulated activity to fine-tune immune responses in autoimmune disorders or infections. Challenges remain in optimizing expression yields and ensuring functional equivalence to native C6. particularly regarding glycosylation effects. Ongoing work aims to harness CF6's mechanistic insights for next-gen immunotherapies and diagnostic tools.
×
